Lacotide 50 Tablet contains Lacosamide 50 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures in patients with epilepsy. Lacosamide acts by selectively enhancing slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing without affecting normal neuronal excitability. This mechanism contributes to its efficacy in reducing seizure frequency and severity. Lacotide 50 is typically administered orally and can be used as monotherapy or adjunctive therapy in adults and pediatric patients aged four years and older. The pharmacokinetic profile of Lacosamide demonstrates rapid absorption with high bioavailability, minimal protein binding, and renal excretion as the primary elimination route. Common adverse effects include dizziness, headache, nausea, and diplopia, which are generally mild to moderate and transient. Caution is advised in patients with cardiac conduction abnormalities, as Lacosamide may prolong PR interval. Dose adjustments may be necessary in renal impairment. Lacotide 50 should be prescribed and monitored by healthcare professionals experienced in epilepsy management, ensuring individualized dosing to optimize therapeutic outcomes while minimizing adverse effects. It is contraindicated in patients with known hypersensitivity to Lacosamide or any excipients in the formulation.